我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

充血性心力衰竭患者口服ACEIs后血浆ox-LDL、vWF及TAC改变的临床意义(PDF)

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2006年第4期
页码:
422-424
栏目:
临床研究
出版日期:
2006-08-25

文章信息/Info

Title:
Effect of angiotensin converting enzyme inhibitors on plasma oxLDL, vWF and TAC levels in patients with congestive heart failure
作者:
杜荣增; 任雨笙; 廖德宁; 黄佐; 黄高忠; 吴宗贵
第二军医大学附属长征医院心内科，上海 200003
Author(s):
DU Rong-zeng;  REN Yu-sheng;  LIAO De-ning;  HUANG Zuo;  HUANG Gao-zhong;  WU Zong-gui
Department of Cardiovasology, Changzheng Hospital Affiliated to Second Military Medical University, Shanghai 200003, China
关键词:
依那普利; 培哚普利; 心力衰竭; 充血性
Keywords:
perindopril;  enalaprol;  heart failure;  congestive
分类号:
R541.6
DOI:
-
文献标识码:
A
摘要:
目的 本研究观察了67例充血性心力衰竭（CHF）患者口服培哚普利和依那普利后血浆氧化型低密度脂蛋白（oxLDL）、血管性假血友病因子（vWF）及总抗氧化能力(TAC)的改变，探讨血管紧张素转换酶抑制剂（ACEIs）对体内氧化状态和血管内皮功能的影响。方法 67例CHF患者随机给予依那普利或培哚普利治疗8周后，观察血浆oxLDL、vWF及TAC水平的改变。35 例健康志愿者作为正常对照组。血浆vWF和oxLDL采用酶标法测定，血浆TAC水平采用分光光度计测定。结果 两组CHF患者基础血浆oxLDL、vWF水平高于健康对照组（P<0.01），血浆TAC水平低于正常对照组（P<0.01）；服药4周后，依那普利组和培哚普利组血浆oxLDL、vWF水平下降（P<0.05），8周后进一步下降（P<0.01）；而血浆TAC水平在4周时升高（P<0.05），8周时进一步升高（P<0.01）。结论 ACEIs如依那普利和培哚普利能提高CHF患者的抗氧化能力，改善血管内皮功能以及降低血栓形成倾向，从而对阻断CHF的恶性循环起到有益作用。
Abstract:
AIM To investigate the changes of plasma von Willebrand factor (vWF), oxidized low density lipoprotein (oxLDL) and total antioxidant capacity (TAC) levels in 67 patients with congestive heart failure after administration of Perindopril or Enalaprol and to discuss the effect of angiotensin convertingenzyme inhibitor (ACEI) on oxidative stress and vascular endothelial function in patients with congestive heart failure. METHODS Plasma TAC level was measured by spectrophotometer and plasma oxLDL and vWF were measured with enzyme linked immunosorbant assay (ELISA). RESULTS The baseline value of plasma TAC in patients with congestive heart failure was lower than that in healthy control subjects and the baseline values of plasma oxLDL and vWF were higher than that in control(P<0.01). The plasma TAC level in Perindopril group and Enalaprol group increased significantly 4 week after the administration (P<0.05) and rose more remarkably 8 week after the administration (P<0.01). The plasma oxLDL and vWF levels decreased 4 week after the administration (P<0.05) and reduced more remarkably 8 week after administration (P<0.01). CONCLUSION ACEIs such as Perindopril and Enalaprol promotes the antioxidative ability and improves the poor vascular endothelial function in these patients, which may play a beneficial role in preventing the deterioration of congestive heart failure.

参考文献/References

［1］ Koracevic D, Koracevic G, Djordjevic V, et al. Method for the measurement of antioxidant activity in human fluids［J］. J Clin Pathol, 2001,54(5):356-361.

［2］ Benson RE, Catalfamo JL, Brooks M, et al. A sensitive immunoassay for von Willebrand factor［J］. J Immunoassay, 1991,12(3):371-390.

［3］ 王华梁，陈思聪，张国元,等. 双抗夹心法检测血浆氧化修饰型低密度脂蛋白［J］. 上海医学检验杂志, 1994，9(3)：135-136.

［4］ Chin BS, Langford NJ, Nuttall SL, et al. Antioxidative properties of betablockers and angiotensinconverting enzyme inhibitors in congestive heart failure ［J］. Eur J Heart Fail,2003,5(2):171-174.

［5］ Indik JH,Goldman S, Gaballa MA. Oxidative stress contributes to vascular endothelial dysfunction in heart failure［J］. Am J Physiol Heart Circ Physiol, 2001,281(4):H1767-H1770.

［6］ de Nigris F, D'armiento FP, Somma P, et al.Chronic treatment with sulfhydryl angiotensinconverting enzyme inhibitors reduce susceptibility of plasma LDL to in vitro oxidation, formation of oxidationspecific epitopes in the arterial wall, and atherogenesis in apolipoprotein E knockout mice［J］. Int J Cardiol, 2001,81(2-3):107-115; discusssion 115-116.

［7］ Chin BS, Gibbs CR, Blann AD, et al. Neither carvedilol nor bisoprolol in maximally tolerated doses has any specific advantage in lowering chronic heart failure oxidant stress: implications for betablocker selection［J］. Clin Sci (Lond), 2003 ,105(4):507-512.

［8］ 张栩，崔云双. 培哚普利对心力衰竭患者血小板活化和内皮功能的影响［J］. 临床心血管病杂志，2001,17(S): 25-27.

［9］ Rajagopalan S,Harrison DG. Reversing endothelial dysfunction with ACE inhibitors. A new trend?［J］. Circulation, 1996,94(3):240-243.

［10］Clapperton M,McMurray J,Fisher AC, et al.The effect of angiotensinconverting enzyme inhibitors on human neutrol chemotaxis in vitro［J］. Br J Clin Pharmacol, 1994,38(1):53-56.

备注/Memo

备注/Memo:
收稿日期：2005-12-29.通讯作者：杜荣增，主治医师，主要从事心脏起搏、电生理及先心病介入治疗研究 Tel：（021）63610109 Email：adu306@sohu.com
更新日期/Last Update: